TH9507 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-06. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake or loose powder |
| Solubility | Freely soluble in water | Salt form dissolves readily in aqueous buffer |
| Storage (lyophilized) | 2 to 8 °C | Protect from light and moisture |
| Common purity method | Reversed-phase HPLC | Reported as peak-area percentage |
| Identity confirmation | Electrospray mass spectrometry | Measured mass compared with theoretical value |
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Cefodizime is a 3rd generation cephalosporin antibiotic with broad spectrum activity against aerobic gram positive and gram negative bacteria. Clinically, it has been shown to be effective against upper and lower respiratory tract infections, urinary tract infections, and gonorrhea. Cefodizime is a bactericidal antibiotic that targets penicillin-binding proteins (PBPs) 1A/B, 2, and 3 resulting in the eventual death of the bacterial cell. In vivo experimental models of infection showed that bacterial clearance by this drug is at least as effective compared with other 3rd generation cephalosporins. It has similar adverse effect profile to other 3rd generation cephalosporins as well, mainly being limited to gastrointestinal or dermatological side effects. It is not currently approved by the FDA for use in the United States.
Salts of many oxidation states of uranium are water-soluble and may be studied in aqueous solutions. The most common ionic forms are U3+ (brown-red), U4+ (green), UO+2 (unstable), and UO2+2 (yellow), for U(III), U(IV), U(V), and U(VI), respectively. A few solid and semi-metallic compounds such as UO and US exist for the formal oxidation state uranium(II), but no simple ions are known to exist in solution for that state. Ions of U3+ liberate hydrogen from water and are therefore considered to be highly unstable. The UO2+2 ion represents the uranium(VI) state and is known to form compounds such as uranyl carbonate, uranyl chloride and uranyl sulfate. UO2+2 also forms complexes with various organic chelating agents, the most commonly encountered of which is uranyl acetate. Unlike the uranyl salts of uranium and polyatomic ion uranium-oxide cationic forms, the uranates, salts containing a polyatomic uranium-oxide anion, are generally not water-soluble.
== Clinical significance == A missense mutation at 17q25 in the GCGR gene is associated with diabetes mellitus type 2. Inactivating mutation of glucagon receptor in humans causes resistance to glucagon and is associated with pancreatic alpha cell hyperplasia, nesidioblastosis, hyperglucagonemia, and pancreatic neuroendocrine tumors, also known as Mahvash disease.
Sources: en.wikipedia.org
=== Pyrimidine dimers === Pyrimidine dimers (also known as thymine dimers) are formed by a photochemical reaction from pyrimidine DNA bases when exposed to ultraviolet light. This cross-linking causes DNA mutations, which can be carcinogenic, causing skin cancers. When pyrimidine dimers are present, they can block polymerases, decreasing DNA functionality until it is repaired.
Bromine oxides are not as well-characterised as chlorine oxides or iodine oxides, as they are all fairly unstable: it was once thought that they could not exist at all. Dibromine monoxide is a dark-brown solid which, while reasonably stable at −60 °C, decomposes at its melting point of −17.5 °C; it is useful in bromination reactions and may be made from the low-temperature decomposition of bromine dioxide in a vacuum. It oxidises iodine to iodine pentoxide and benzene to 1,4-benzoquinone; in alkaline solutions, it gives the hypobromite anion. So-called "bromine dioxide", a pale yellow crystalline solid, may be better formulated as bromine perbromate, BrOBrO3. It is thermally unstable above −40 °C, violently decomposing to its elements at 0 °C. Dibromine trioxide, syn-BrOBrO2, is also known; it is the anhydride of hypobromous acid and bromic acid. It is an orange crystalline solid which decomposes above −40 °C; if heated too rapidly, it explodes around 0 °C. A few other unstable radical oxides are also known, as are some poorly characterised oxides, such as dibromine pentoxide, tribromine octoxide, and bromine trioxide. The four oxoacids, hypobromous acid (HOBr), bromous acid (HOBrO), bromic acid (HOBrO2), and perbromic acid (HOBrO3), are better studied due to their greater stability, though they are only so in aqueous solution. When bromine dissolves in aqueous solution, the following reactions occur:
The first company to use such method is Evonik company in 2000. The enzyme Lipase-CalB in its immobilized state is actually used in other pharmaceutical applications for the production of Odanacatib, and Sofosbuvir.
=== Research === A 2023 study on genetically engineered mice published in the journal PNAS found that increasing production of a particular microRNA in hair follicle stem cells, which naturally harden with age, softened the cells and stimulated hair growth. The authors of the study said the next research step is to introduce the microRNA into the stem cells using nanoparticles applied directly to the skin, to develop a similar topical application for humans.
Sources: en.wikipedia.org
Tejo is Colombia's national sport and is a team sport that involves launching projectiles to hit a target. But of all sports in Colombia, football is the most popular. Colombia was the champion of the 2001 Copa América, in which they set a new record of being undefeated, conceding no goals and winning each match. Colombia has been awarded "mover of the year" twice. Colombia is a hub for roller skaters. The national team is a perennial powerhouse at the World Roller Speed Skating Championships. Colombia has traditionally been very good in cycling and a large number of Colombian cyclists have triumphed in major competitions of cycling. Baseball is popular in cities like Cartagena and Barranquilla. Of those cities have come good players like: Orlando Cabrera, Édgar Rentería, who was champion of the World Series in 1997 and 2010 and others who have played in Major League Baseball. Colombia was world amateur champion in 1947 and 1965. Boxing is one of the sports that has produced more world champions for Colombia. Motorsports also occupies an important place in the sporting preferences of Colombians; Juan Pablo Montoya is a race car driver known for winning 7 Formula One events. Colombia also has excelled in sports such as BMX, judo, shooting sport, taekwondo, wrestling, high diving and athletics, also has a long tradition in weightlifting and bowling.
Pseudoephedrine induces monoamine release in vitro with an EC50Tooltip half maximal effective concentration of 224 nM for norepinephrine and 1,988 nM for dopamine, whereas it is inactive for serotonin. As such, it is about 9-fold selective for induction of norepinephrine release over dopamine release. The drug has negligible agonistic activity at the α1- and α2-adrenergic receptors (Kact >10,000 nM). At the β1- and β2-adrenergic receptors, it acts as a partial agonist with relatively low affinity (β1 = Kact = 309 μM, IATooltip intrinsic activity = 53%; β2 = 10 μM; IA = 47%). It was an antagonist or very weak partial agonist of the β3-adrenergic receptor (Kact = ND; IA = 7%). It is about 30,000 to 40,000 times less potent as a β-adrenergic receptor agonist than (–)-isoproterenol. Pseudoephedrine's principal mechanism of action relies on its action on the adrenergic system. The vasoconstriction that pseudoephedrine produces is believed to be principally an α-adrenergic receptor response. Pseudoephedrine acts on α- and β2-adrenergic receptors, to cause vasoconstriction and relaxation of smooth muscle in the bronchi, respectively. α-Adrenergic receptors are located on the muscles lining the walls of blood vessels. When these receptors are activated, the muscles contract, causing the blood vessels to constrict (vasoconstriction). The constricted blood vessels now allow less fluid to leave the blood vessels and enter the nose, throat, and sinus linings, which results in decreased inflammation of nasal membranes, as well as decreased mucus production.
Investigation on MMP inhibitors with phosphorus based zinc binding groups focused on α-biphenylsulfonylamino phosphonates. These inhibitors bind through two phosphonate oxygen atoms. Phosphonate inhibitors have been developed that exhibit selectivity for MMP-8 over other MMPs. Selective MMP-8 inhibitors could be useful in the treatment of acute liver disease and multiple sclerosis Phosphinic MMP inhibitors have been reported to target MMP-11 and MMP-13. MMP-13 plays a role in cartilage degradation in osteoarthritis. These phosphinate MMP inhibitors contain phenyl segments that are thought to be responsible for the selectivity to MMP-13. The phosphinic group of those inhibitors (R1R2 (O)OH) binds as a zinc ligand. R1 and R2 substituents affect the inhibition potency. Phosphinate inhibitors have been developed that showed high selectivity for MMP-11. Derivatives based on phenyl rings showed the best selectivity. MMP-11 could be a useful target for tumorgenesis in breast cancer.
Greater emphasis on risk management Introduces “Special Requirements” Introduces “Critical Items” Measure: Requirements conformance Measure: Delivery performance Adopt proven product development processes Eliminate “recurring corrective actions” AS9100 Revision C was released in January, 2009, with considerable delay in application of the new version in audits, largely due to the delay in the release of AS9101 Revision D and auditor training to the increased auditing rigor of that update. AS9100 Revision D (2016), Quality Management System – Requirements for Aviation, Space and Defense Organizations The update of AS9100 from revision C to D includes the full text of ISO 9001:2015. In addition to aligning the structure of the aviation, space and defense requirements to the new structure of ISO 9001:2015, the following key changes were implemented:
CO2 + 4 H2S + O2 → CH2O + 4 S0 + 3 H2O CO2 + H2S + O2 + H2O → CH2O + SO2–4 + 2 H+ In modern oceans, Thiomicrospira, Halothiobacillus, and Beggiatoa are primary sulfur oxidizing bacteria, and form chemosynthetic symbioses with animal hosts. The host provides metabolic substrates (e.g., CO2, O2, H2O) to the symbiont while the symbiont generates organic carbon for sustaining the metabolic activities of the host. The produced sulfate usually combines with the leached calcium ions to form gypsum, which can form widespread deposits on near mid-ocean spreading centers. Sulfur metabolizing microbes are often engaged in close symbiotic relationships with other microbes, and even animals. PSB and sulfate reducers form microbial aggregates called “pink berries” in the salt marshes of Massachusetts within which sulfur cycling occurs through the direct exchange of sulfur species. The Vestimentiferan tube worms that grow around hydrothermal vents lack a digestive tract but contain specialized organelles called trophosomes within which autotrophic, sulfide oxidizing bacteria are housed. The tube worms provide the bacteria with sulfide and the bacteria shares the fixed carbon with the worms.
Sources: en.wikipedia.org
Reconstituted solutions are kept cold and used within the period stated on the label or certificate. Repeated warming and cooling cycles should be avoided because they encourage aggregation and gradual loss of potency.
Mass spectrometry serves as the primary identity check, since the measured mass must agree with the theoretical value for a 44-residue sequence. Chromatographic retention time and peptide mapping supply supporting evidence.
Certificates of analysis and independent testing tie a specific lot to specific measured results. Without that link, purity and identity claims rest on the supplier's own statement rather than on verifiable data.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.